跳到正文
ECA GMP News·· 21 天前AI 评分73

PIC/S 发布 PI 058-1 问答文件阐释无菌药品生产附录1修订要点

PIC/S publishes a Q&A document to assist with Annex 1

AI 导读

PIC/S 发布 PI 058-1 问答文件,对无菌药品生产附录1修订后的关键问题给出统一技术解释,文件于 2026 年 10 月 16 日经 PIC/S 委员会通过、10 月 28 日生效。

正文 · 原文

PIC/S has published a new interpretation of the revised Annex 1 in PI 058-1, "Interpretation of the Most Important Changes in the Annex 1 on the Manufacture of Sterile Products (2022)". The document was adopted by the PIC/S Committee on 16 October 2026 and entered into force on 28 October 2026. Its purpose is to support the harmonised conduct of inspections and provide a common technical interpretation of key questions that have arisen since the Annex was revised and implemented. PIC/S explicitly clarifies that PI 058-1 is not intended to introduce new GMP requirements, but to explain existing ones.The document's origins are particularly relevant. The initial draft was prepared by Swissmedic in 2023 (I-SMI.TI.25e). It served as the starting point for the work of the joint PIC/S-EMA-WHO Working Group on the implementation of the revised Annex 1. The draft was subsequently reviewed by PIC/S members, the EMA working group and WHO. The aim is to ensure a consistent technical interpretation across PIC/S, the EU and WHO.PIC/S explains that the draft prepared by Swissmedic in 2023 served as the basis for the joint PIC/S-EMA-WHO Working Group. The resulting document was then reviewed internationally and is intended to support a harmonised technical interpretation. It is therefore not simply an unchanged adoption of the Swissmedic Q&As. At the same time, many topics were already covered in I-SMI.TI.25e, including material transfers, WFI, PUPSIT, single-use systems, environmental monitoring and APS. PI 058-1 revisits these questions and further explains them within a harmonised framework.One clear example of the expanded scope is the section on scope. The Swissmedic Q&As begin by asking how Annex 1 applies to ATMPs. PI 058-1 instead explicitly addresses whether a CCS may also be relevant to the manufacture of non-sterile products and further explains the structure and regular review of the CCS. Other points addressed in greater detail include the distinction between VHP bio-decontamination and sterilisation, as well as requirements for initial personnel qualification and possible disqualification.What are the main topics covered by PI 058-1? Scope and general principles: CCS, material testing and risk-based interim measures for facilities that are not yet fully compliant; the objective remains to achieve full compliance with the requirements. Premises and equipment: Material transfers, isolator risk assessments, airflow, disinfection, and the distinction between bio-decontamination and sterilisation. VHP is not treated as a sterilisation method in all cases. Utilities and personnel: WFI monitoring, process gases, qualification in aseptic behaviour, and the conditions for unsupervised access to Grade A and B areas. Production and specific technologies: Container and single-use system integrity, sterilisation validation, PUPSIT, aseptic connections, and the design of Aseptic Process Simulations (APS). Environmental and process monitoring, and QC: Trend assessment and alert/action limits, Rapid Microbiological Methods (RMM) and the conditions for using them as alternatives or supplementary rapid methods, APS scope and frequency, and bioburden testing before final sterilisation.The CCS is a central theme throughout the document. The ECA guide "How to Develop and Document a Contamination Control Strategy," can also be used as practical support when preparing a CCS. It describes a structured approach that includes mapping processes, identifying potential sources of contamination, assessing risks, and defining preventive controls and responsibilities. The guide complements PI 058-1 as a support, but does not replace regulatory requirements or a site-specific assessment. A CCS must be tailored to the product, process, facility and existing control systems.In summary, the new PIC/S Q&A document, PI 058-1, is primarily an interpretative and harmonisation step. Manufacturers and inspectors would be well advised to focus specifically on the CCS, procedures and qualification programmes covering the topics outlined – particularly where national Q&As or internal interpretations have thus far served as guidance.

来源:ECA GMP News · gmp-compliance.org

事件后续 · 1

查看事件全部